Patents Assigned to Health Research, Inc.
-
Patent number: 11779256Abstract: Provided is a method for mapping a neural area involved in speech processing, including applying a plurality of recording electrodes to a surface of a cortex of a human subject, presenting a plurality of auditory stimuli to the subject wherein some of the plurality of stimuli are speech sounds and others of the plurality of auditory stimuli are non-speech sounds, recording brain activity during the presenting of the plurality of auditory stimuli, and identifying one or more brain areas wherein activity changes more after presentation of speech sounds than it does after presentation of non-speech sounds, wherein the human subject does not speak during the presenting and the recording. Also provided is a method for mapping a neural area involved in speech production wherein the human subject does not speak during presenting speech stimuli and recording neural activity.Type: GrantFiled: July 1, 2021Date of Patent: October 10, 2023Assignees: HEALTH RESEARCH, INC., ALBANY MEDICAL COLLEGEInventors: Gerwin Schalk, Anthony L. Ritaccio, Adriana De Pesters, AmiLyn Taplin
-
Patent number: 11771750Abstract: Provided is an immunogenic composition including a peptide, wherein consecutive amino acids of the peptide include at least amino acids 186-193 of SEQ ID NO:1 and one or more adjuvants. In an example, the peptide is covalently linked to an amino acid sequence including SEQ ID NO:2. Also provided is a method of vaccinating a subject against Borrelia burgdorferi, including administering to the subject an effective amount of the immunogenic composition.Type: GrantFiled: March 28, 2022Date of Patent: October 3, 2023Assignees: HEALTH RESEARCH, INC., LATVIAN BIOMEDICAL RESEARCH AND STUDY CENTERInventors: Yi-Pin Lin, Kaspars Tars
-
Patent number: 11773181Abstract: Provided are survivin specific antibodies, nucleic acids encoding the antibodies and methods for treating tumors comprising survivin-expressing cells by administration of the antibodies. The antibody compositions were found to be effective in inhibiting the growth of tumors.Type: GrantFiled: August 11, 2020Date of Patent: October 3, 2023Assignee: Health Research, Inc.Inventors: Robert A. Fenstermaker, Michael J. Ciesielski
-
Patent number: 11767303Abstract: The present disclosure relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof. The present disclosure further relates to methods of inhibiting viral replication including contacting one or more cells that have been infected with a virus with an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein the virus comprises a flavivirus. Also disclosed is a method of treating and/or preventing a flavivirus infection and/or a condition resulting from a flavivirus infection including administering an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof under conditions effective to treat and/or prevent a flavivirus infection and/or a condition resulting from a flavivirus infection.Type: GrantFiled: July 23, 2021Date of Patent: September 26, 2023Assignees: HEALTH RESEARCH, INC., BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONAInventors: Hongmin Li, Zhong Li, Jia Zhou, Jimin Xu, Qing-Yu Zhang
-
Publication number: 20230233533Abstract: The present disclosure relates to a Prp8 intein splicing inhibitor. The present disclosure further relates to a method of treating and/or preventing a fungal infection, said method comprising administering a Prp8 intein splicing inhibitor under conditions effective to treat and/or prevent a fungal infection. Also disclosed is a method of inhibiting Prp8 intein expression or activity in a cell or tissue, said method comprising administering a compound under conditions effective to inhibit Prp8 intein expression or activity in a cell or tissue. Further disclosed are methods for screening for compounds that inhibit Prp8 intein splicing comprising an assay and a kit for predicting the likelihood of Prp8 inhibition.Type: ApplicationFiled: April 9, 2021Publication date: July 27, 2023Applicants: Health Research, Inc., The Board of Regents of the University of Texas SystemInventors: Hongmin LI, Zhong LI, Jia ZHOU, Jimin XU
-
Patent number: 11672855Abstract: Disclosed is an adapted Madin-Darby canine kidney cell line capable of suspension culture in the absence of serum, and a chemically-defined medium for culture of the adapted MDCK cell line. Further disclosed are culture methods for growing the adapted MDCK cell line and methods for producing a vaccine from the adapted MDCK cell line grown in the chemically-defined medium.Type: GrantFiled: September 28, 2020Date of Patent: June 13, 2023Assignees: NATIONAL HEALTH RESEARCH INSTITUTES, FUJIFILM IRVINE SCIENTIFIC, INC.Inventors: Jenny Bang, Hsiao-Tzu Ni, Alan Yung-Chih Hu, Tsai-Chuan Weng
-
Patent number: 11662350Abstract: Provided is a method of detecting the presence of an anti-Zika virus (ZIKV) antibody in a sample, including contacting a sample with a suspension having a plurality of microspheres wherein individual microspheres are conjugated to a peptide and the peptide includes a ZIKV peptide selected from the group including ZIKV NS1, ZIKV NS5, and ZIKV envelope protein, forming a first incubated suspension by incubating said sample with said suspension to permit binding of anti-ZIKV antibodies present in the sample to said microspheres, forming a second incubated suspension by contacting said first incubated suspension with an anti-ZIKV antibody detecting-reagent to permit binding of the anti-ZIKV antibody detecting reagent to said microspheres, removing from the second incubated suspension anti-ZIKV antibody detecting-reagent molecules that are not bound to said microspheres, and detecting the presence of anti-ZIKV antibody detecting-reagent molecules in the second incubated suspension.Type: GrantFiled: November 29, 2021Date of Patent: May 30, 2023Assignee: HEALTH RESEARCH, INC.Inventors: Susan J. Wong, Pei-Yong Shi
-
Publication number: 20230146253Abstract: The technology described herein is directed to methods of treating and diagnosing bronchial premalignant lesions, e.g. by determining the lesion subtype using one or more biomarkers described herein.Type: ApplicationFiled: January 4, 2023Publication date: May 11, 2023Applicants: TRUSTEES OF BOSTON UNIVERSITY, HEALTH RESEARCH, INC.Inventors: Jennifer E. Beane-Ebel, Avrum E. Spira, Marc Lenburg, Mary E. Reid, Sarah Mazzilli
-
Patent number: 11617741Abstract: Provided is a method for inhibiting the growth of Gram-positive bacteria, including contacting said bacteria with a first compound and a second compound, wherein the first compound is a compound of Formula I: and the second compound is an antibiotic other than a compound of Formula I. Also provided is a composition including the first compound and the second compound.Type: GrantFiled: August 12, 2021Date of Patent: April 4, 2023Assignees: HEALTH RESEARCH, INC., THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK, DUKE UNIVERSITYInventors: Ville Vare, Kathleen McDonough, Ryan Schneider, Paul Agris, Thorsten Seyler
-
Publication number: 20230102223Abstract: Provided is a method of inhibiting viral replication, including contacting one or more cells that has been infected or contacted with a flavivirus with an effective amount of niclosamide, temoporfin, nitazoxanide, tizoxanide, erythrosin B, methylene blue. Contacting one or more cells that have been infected with a flavivirus may include administering the compound to a mammal, a human, or other subject. The flavivirus may be Dengue virus serotype 1, Dengue virus serotype 2, Dengue virus serotype 3, Dengue virus serotype 4, yellow fever virus, West Nile virus, Zika virus, Japanese encephalitis virus, tick-born encephalitis virus, Powassan virus, St. Louis encephalitis virus, or other flavivirus.Type: ApplicationFiled: October 27, 2022Publication date: March 30, 2023Applicants: HEALTH RESEARCH, INC., THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICInventors: Hongmin LI, Laura D. KRAMER, Zhong LI, Ruili HUANG, Menghang XIA
-
Patent number: 11579140Abstract: The technology described herein is directed to methods of treating and diagnosing bronchial premalignant lesions, e.g. by determining the lesion subtype using one or more biomarkers described herein.Type: GrantFiled: August 20, 2019Date of Patent: February 14, 2023Assignees: TRUSTEES OF BOSTON UNIVERSITY, HEALTH RESEARCH, INC.Inventors: Jennifer E. Beane-Ebel, Avrum E. Spira, Marc Lenburg, Mary E. Reid, Sarah Mazzilli
-
Patent number: 11491123Abstract: Provided is a method of inhibiting viral replication, including contacting one or more cells that has been infected or contacted with a flavivirus with an effective amount of niclosamide, temoporfin, nitazoxanide, tizoxanide, erythrosin B, methylene blue. Contacting one or more cells that have been infected with a flavivirus may include administering the compound to a mammal, a human, or other subject. The flavivirus may be Dengue virus serotype 1, Dengue virus serotype 2, Dengue virus serotype 3, Dengue virus serotype 4, yellow fever virus, West Nile virus, Zika virus, Japanese encephalitis virus, tick-born encephalitis virus, Powassan virus, St. Louis encephalitis virus, or other flavivirus.Type: GrantFiled: June 23, 2017Date of Patent: November 8, 2022Assignees: HEALTH RESEARCH, INC., THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICESInventors: Hongmin Li, Laura D. Kramer, Zhong Li, Ruili Huang, Menghang Xia
-
Patent number: 11467152Abstract: Provided is a method for evaluating the progression of glioma in an individual comprising monitoring the levels of circulating exosomes that are positive for survivin and a glial marker (such as glial fibrillary acidic protein). An increase in the level of such exosomes is indicative of poor prognosis. Levels of circulating exosomes that are positive for survivin and glial marker can also be used for evaluating the efficacy of a therapy for glioma in an individual, and modifying the therapy or introducing additional therapy if levels of such exosomes are found to be increasing.Type: GrantFiled: December 18, 2017Date of Patent: October 11, 2022Assignee: Health Research, Inc.Inventors: Robert A. Fenstermaker, Michael J. Ciesielski
-
Publication number: 20220280627Abstract: Provided is an immunogenic composition including a peptide, wherein consecutive amino acids of the peptide include at least amino acids 186-193 of SEQ ID NO:1 and one or more adjuvants. In an example, the peptide is covalently linked to an amino acid sequence including SEQ ID NO:2.Type: ApplicationFiled: March 28, 2022Publication date: September 8, 2022Applicant: Health Research, Inc.Inventor: Yi-Pin LIN
-
Patent number: 11344742Abstract: A system and method are disclosed that use a flexible guide (flap) and a scanning method to control the delivery of light dose to a treatment area. This approach overcomes the non-reliable delivery of light dose with a flap that conforms to the target area. Dosimetry control can be improved through the use of a computer controlled motor to move the laser fibers at known speed over the target tissue. In some embodiments, treatment time is reduced and illumination of large surfaces is achieved by using multiple fibers to deliver the light simultaneously.Type: GrantFiled: July 25, 2016Date of Patent: May 31, 2022Assignee: Health Research, Inc.Inventors: Gal Shafirstein, Brian Wrazen, David A. Bellnier, Todd Demmy
-
Publication number: 20220125057Abstract: Disclosed herein are novel anti-microbial peptides with inhibitory activity against M. tuberculosis and streptococcus bacteria. Additionally, a method for designing novel anti-microbial peptides is disclosed.Type: ApplicationFiled: November 10, 2021Publication date: April 28, 2022Applicants: RENSSELAER POLYTECHNIC INSTITUTE, HEALTH RESEARCH, INC.Inventors: Georges BELFORT, C. Seth PEARSON, Brian MURRAY, Pankaj Sakharam KARANDE, Jun Ha KWAK, Kathleen A. MCDONOUGH, Zachary Andrew KLOOS
-
Publication number: 20220125744Abstract: To induce cancer cell death, cancer cells are selected that express estrogen-receptor ? (ER?) and mutant tumor protein 53 (TP53). An agent that increases ER? protein expression is administered to the cells to induce cell death. To treat a subject having a cancer that is characterized by cancer cells expressing ER? and mutant TP53, an agent that increases ER? protein expression is administered to induce cell death in the cancer cells. To increase estrogen receptor ? (ER?) expression levels in a subject having low ER? expression levels, tamoxifen is administered to increase ER? protein levels in the subject. To treat a subject having cancer cells expressing estrogen-receptor ? (ER?) and wildtype tumor protein 53 (TP53), an agent that inhibits ER? and TP53 binding interaction is administered to induce cell death in the cancer cells of the subject.Type: ApplicationFiled: November 7, 2019Publication date: April 28, 2022Applicant: Health Research, Inc.Inventor: Gokul M. Das
-
Publication number: 20220099681Abstract: Provided is a method of detecting the presence of an anti-Zika virus (ZIKV) antibody in a sample, including contacting a sample with a suspension having a plurality of microspheres wherein individual microspheres are conjugated to a peptide and the peptide includes a ZIKV peptide selected from the group including ZIKV NS1, ZIKV NS5, and ZIKV envelope protein, forming a first incubated suspension by incubating said sample with said suspension to permit binding of anti-ZIKV antibodies present in the sample to said microspheres, forming a second incubated suspension by contacting said first incubated suspension with an anti-ZIKV antibody detecting-reagent to permit binding of the anti-ZIKV antibody detecting reagent to said microspheres, removing from the second incubated suspension anti-ZIKV antibody detecting-reagent molecules that are not bound to said microspheres, and detecting the presence of anti-ZIKV antibody detecting-reagent molecules in the second incubated suspension.Type: ApplicationFiled: November 29, 2021Publication date: March 31, 2022Applicants: Health Research, Inc., The Board of Regents of The University of Texas SystemInventors: Susan J. WONG, Pei-Yong SHI
-
Patent number: 11285198Abstract: Provided is an immunogenic composition including a peptide, wherein consecutive amino acids of the peptide include at least amino acids 186-193 of SEQ ID NO:1 and one or more adjuvants. In an example, the peptide is covalently linked to an amino acid sequence including SEQ ID NO:2. Also provided is a method of vaccinating a subject against Borrelia burgdorferi, including administering to the subject an effective amount of the immunogenic composition.Type: GrantFiled: June 3, 2020Date of Patent: March 29, 2022Assignee: HEALTH RESEARCH, INC.Inventor: Yi-Pin Lin
-
Patent number: 11254914Abstract: Compositions and methods are provided for converting the predominant circulating classical monocytes to a non-classical and/or intermediate monocyte phenotype through cytokine stimulation via, for example, macrophage colony-stimulating factor. Once cultured into dendritic cells, these non-classical and/or intermediate monocyte derived cells have increased costimulatory molecule expression, which leads to improved immune and clinical responses in cancer patients receiving dendritic cell vaccination and other immunotherapies. In addition, assays and diagnostic and theranostic methods are provided herein that relate to the discoveries that, prior to treatment, intermediate (CD14+CD16+) and non-classical (CD14dimCD16+) monocytes are increased more than two-fold in patients who later had complete responses to dendritic cell therapy or DC vaccination.Type: GrantFiled: March 11, 2016Date of Patent: February 22, 2022Assignee: HEALTH RESEARCH, INC.Inventors: Thomas Schwaab, Jason Bryan Muhitch